Business
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being held February 26-28, 2026, in San Francisco, California.
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being held February 26-28, 2026, in San Francisco, California.","length":493,"tagName":"p"},{"type":"text","content":"Details of the poster presentations are below:","length":46,"tagName":"p"},{"type":"text","content":"Title: "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial"","length":148,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Abstract Number: 809","length":20,"tagName":"p"}]},{"val":[{"type":"text","content":"Session: Poster Session B: Prostate Cancer and Urothelial Carcinoma","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Date and Time: February 27, 2026, 11:30 AM–12:45 PM PST","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenting Author: Andrew J. Murtha, BSc, University of British Columbia, Vancouver, BC, Canada","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":237,"olType":false},{"type":"text","content":"Title: "A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (formerly TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)"","length":238,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Abstract Number: TPS886","length":23,"tagName":"p"}]},{"val":[{"type":"text","content":"Session: Trials in Progress Poster Session B: Urothelial Carcinoma","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Date and Time: February 27, 2026, 11:30 AM–12:45 PM PST","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenting Author: Gautam Jayram, MD, Urology Associates, Nashville, TN","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":215,"olType":false},{"type":"text","content":"More information can be found at the ASCO GU website. The posters will b...